Clinical trial NCT06777485: China Liver Cancer Clinical Registry Cohort Database
Official title: China Liver Cancer Clinical Registry Cohort Database
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Cancer
Lead sponsor: Anhui Provincial Hospital
Sponsor class: OTHER_GOV
First posted: 2025-01-15
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular carcinoma-cholangiocarcinoma, or metastatic liver cancer.

Brief summary: This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years, no gender limit
* Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
* Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples

Exclusion Criteria:

* Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
* Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
* Pregnant or breastfeeding women
* Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected

Primary outcomes:
measure: OS
timeFrame: 10 years
Secondary outcomes:
measure: RFS
timeFrame: 10 years
measure: Survival time after recurrence
timeFrame: 10 years
Other outcomes:
Locations:
city: Anqing
country: China
facility: Anqing First People's Hospital
state: Anhui
city: Anqing
country: China
facility: Anqing Municipal Hospital
state: Anhui
city: Bengbu
country: China
facility: Bengbu First People's Hospital
state: Anhui
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical University
state: Anhui
city: Bengbu
country: China
facility: The Second Affiliated Hospital of Bengbu Medical College
state: Anhui
city: Bozhou
country: China
facility: The People's Hospital of Bozhou
state: Anhui
city: Chizhou
country: China
facility: The People's Hospital of Chizhou
state: Anhui
city: Chuzhou
country: China
facility: The First People's Hospital of Chuzhou
state: Anhui
city: Fuyang
country: China
facility: No.2 People's Hospital of Fuyang City
state: Anhui
city: Fuyang
country: China
facility: Fuyang Cancer Hospital
state: Anhui
city: Fuyang
country: China
facility: Fuyang Fifth People's Hospital
state: Anhui
city: Fuyang
country: China
facility: Fuyang People's Hospital
state: Anhui
city: Fuyang
country: China
facility: Fuyang Sixth People's Hospital
state: Anhui
city: Fuyang
country: China
facility: Funan County People's Hospital
state: Anhui
city: Fuyang
country: China
facility: Taihe County People's Hospital
state: Anhui
city: Hefei
country: China
facility: Anhui province hospital
state: Anhui
city: Hefei
country: China
facility: Anhui Provincial Cancer Hospital
state: Anhui
city: Hefei
country: China
facility: Hefei Binhu Hospital
state: Anhui
city: Hefei
country: China
facility: Hefei First People's Hospital
state: Anhui
city: Hefei
country: China
facility: The First Affiliated Hospital of Anhui Medical University
state: Anhui
city: Hefei
country: China
facility: The Second Hospital of Anhui Medical University
state: Anhui
city: Hefei
country: China
facility: The Second People's Hospital of Hefei
state: Anhui
city: Hefei
country: China
facility: Anhui Second People's Hospital
state: Anhui
city: Huaibei
country: China
facility: Huaibei Mining General Hospital
state: Anhui
city: Huaibei
country: China
facility: Huaibei People's Hospital
state: Anhui
city: Huainan
country: China
facility: Huainan First People's Hospital
state: Anhui
city: Huainan
country: China
facility: Huainan Oriental Hospital
state: Anhui
city: Huainan
country: China
facility: Huainan Sunshine Xinkang Hospital
state: Anhui
city: Huainan
country: China
facility: Huainan Xinhua Hospital
state: Anhui
city: Huangshan
country: China
facility: Huangshan City People's Hospital
state: Anhui
city: Huangshan
country: China
facility: Huangshan Shoukang Hospital
state: Anhui
city: Lu'an
country: China
facility: Lu'an People's Hospital
state: Anhui
city: Suzhou
country: China
facility: Suzhou Hospital of Anhui Medical University
state: Anhui
city: Tongling
country: China
facility: Tongling People's Hospital
state: Anhui
city: Wuhu
country: China
facility: The Second People's Hospital of Wuhu
state: Anhui
city: Wuhu
country: China
facility: The First Affiliated Hospital of Wannan Medical College
state: Anhui
city: Xuancheng
country: China
facility: Xuancheng People's Hospital
state: Anhui
city: Zhengzhou
country: China
facility: Henan Provincial People's Hospital
state: Henan
Study officials:
References: